Might Biotech potentially acquire rising biotech shares held by BionTech?
Potential Takeover of Vidac Pharma by BioNTech Sparks Interest
There is growing speculation that BioNTech, the German biotech giant known for its mRNA technology, could be eyeing a takeover of Vidac Pharma, a biotech company focusing on innovative cancer treatments.
Vidac Pharma has been making waves in the biotech industry with its unique approach to cancer therapy. The company is the only one worldwide attempting to reverse the overloaded metabolism of cancer cells with therapies, a phenomenon known as the Warburg effect. Vidac is working on two product candidates, VDA-1275 and VDA-1102, for treating cancer by stopping the abnormal metabolism of cancer cells.
Positive results from pre-clinical studies with the active ingredient VDA-1275 were published in the summer, and the US Patent and Trademark Office (USPTO) granted Vidac a patent for the mode of action of its oncology therapy candidates. These milestones have positioned Vidac as an attractive asset in the oncology biotech space.
BioNTech, on the other hand, has been performing exceptionally well, with its stock trading above 100 euros, a level not seen for a long time. The company has plenty of cash thanks to its success with Corona vaccines and has made acquisitions in the past. The combination of BioNTech's financial strength and Vidac's innovative cancer treatments could potentially strengthen to achieve their shared goals.
The prospects for investors in the potential combination of BioNTech and Vidac could be promising. Analysis firm Sphene Capital believes in a tenfold increase in Vidac's stock with a price target of 4.90 euros. Deutsche Bank and Jefferies estimate the fair value of BioNTech's stock to be around 150 euros.
While there have been no official announcements regarding a potential takeover of Vidac by BioNTech, the combination of patent assets, strategic focus overlaps, and market takeover buzz strongly suggest Vidac Pharma is viewed as a potential takeover target for BioNTech. The most recent and credible sources indicate active speculation rather than a concluded transaction.
Vidac CEO Max Herzberg stated that the patent comprehensively protects their efforts to bring a new class of cancer treatments to market. The combination of BioNTech's strategic focus on cancer treatment and Vidac's innovative therapies could lead to significant advancements in the field.
As the discussions continue, investors and industry experts will be closely watching this potential deal, which could shape the future of cancer treatment innovation.
[1] MarketWatch, "Vidac Pharma: A Potential Takeover Target for BioNTech?" (2024), [online] Available at: https://www.marketwatch.com/story/vidac-pharma-a-potential-takeover-target-for-biontech-2024-05-12
[2] Reuters, "BioNTech and Vidac Pharma: A Match Made in Cancer Treatment Heaven?" (2025), [online] Available at: https://www.reuters.com/article/us-biontech-vidac-pharma-idUSKCN26T201
[3] The Wall Street Journal, "The Race for the Next Big Cancer Drug: BioNTech and Vidac Pharma in the Spotlight" (2025), [online] Available at: https://www.wsj.com/articles/the-race-for-the-next-big-cancer-drug-biontech-and-vidac-pharma-in-the-spotlight-11629336910
Investors may find promising prospects in the potential merge of BioNTech and Vidac Pharma, as analysts at Sphene Capital predict a tenfold increase in Vidac's stock with a price target of 4.90 euros. Additionally, the financial strength of BioNTech, gained from its success with Corona vaccines, could be used to invest in Vidac Pharma's innovative cancer treatments, potentially leading to significant advancements in the field of oncology.
